Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Physicians' Prescribing Preferences for the Usage of Anti-Diabetic and Anti-Obesity Medications for Effective Weight Management in Iraq.

Created on 19 Nov 2026

Authors

Khansaa A Ibrahim Albaroodi

Published in

Journal of primary care & community health. Volume 17. Pages 21501319261504064. Epub Nov 18, 2026.

Abstract

PurposeThere is limited data on weight management medications in Iraq; therefore, this pilot study aimed to assess physicians' prescribing preferences for anti-diabetic and anti-obesity to support effective weight management.MethodsThis pilot study targeted healthcare professionals working in weight-loss clinics in Iraq; participants from four provinces: Karbala, Najaf, Diwaniya, and Hilla were included. Conducted between October 1, 2024, and December 31, 2024. The study used convenience sampling. Results were obtained by using SPSS (version 20).ResultsAmong 15 participants aged 44.6±8.3 years (ranging from 29 to 60 years), with 7.6±3.6 years (ranging from 2 to 14 years) of experience in nutrition, approximately 40% preferred either metformin or orlistat. Side effects that restricted medication use were nausea, dizziness, and diarrhea, with 40%, 33.3%, and 20%, respectively. All medication were assessed preference items on a dichotomous (yes/no) scale. No multi-item scale was used; therefore, range-based interpretation is not applicable. Preferences are reported as percentages of participants selecting each medication. No significant associations were observed between medications and comorbidities, except that semaglutide preference was positively associated with consideration of general health factors (Cramér's V = 1.000, p = 0.0001), indicating a strong effect size despite the small sample. No statistically significant difference in preference frequency was observed between metformin and orlistat (p = 0.132). Preference for semaglutide was not significantly lower than for metformin (p = 0.486, Fisher's exact test).ConclusionThis pilot study highlights obesity management and the need for transitioning from a weight-centric model to a comprehensive metabolic health framework. In practical terms, this includes routine comorbidity assessment before prescribing, using GLP-1 agonists for patients with obesity and cardiovascular risk factors, and insurance or subsidy policies to improve access to newer agents. As a pilot study with a small convenience sample (n=15), findings are preliminary and require validation in larger, multi-region Iraqi samples.

PMID:
43050597
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement